HBA names Shire's Sibley Woman of the Year

Share this article:
Shire's Sibley: HBA WOTY
Shire's Sibley: HBA WOTY

At a luncheon May 8, the Healthcare Businesswomen's Association (HBA) awarded Charlotte Sibley Woman of the Year for 2008. Sibley is senior vice president, leadership development, at Shire Pharmaceuticals.

In a speech during the event, held at the Hilton in New York City, Sibley underscored the importance of quality leadership.  "Would you want to work for you?" Sibley asked over 2,000 attendees at the luncheon.  Quoting Maya Angelou, Sibley said, "people will forget what you said, people will forget what you did, but people will never forget how you made them feel." Prior to her position at Shire, Sibley worked for Pharmacia Corporation (now Pfizer), Johnson & Johnson and Bristol-Myers Squibb.

Other awards given at the ceremony included the 2008 Honorable Mentor, to Leonard Kanavy, VP commercial operations at Genentech, and the Star Volunteer award, to Anne Camille Talley, an industry consultant with Health Leaders Consultancy.

Additionally, 95 “Rising Stars,” described as “up-and-coming professionals” in the healthcare industry, were recognized by the HBA at the luncheon.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...